Ameriprise
PRCT icon

Ameriprise’s Procept Biorobotics PRCT Stock Holding History

Ameriprise’s Portfolio PRCT Stock Details PRCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$890K Sell
35,599
-3,414
-9% -$96.2K ﹤0.01% 3351
2025
Q4 		$1.23M Sell
39,013
-38,203
-49% -$1.27M ﹤0.01% 3235
2025
Q3 		$2.76M Sell
77,216
-43,500
-36% -$1.99M ﹤0.01% 2822
2025
Q2 		$6.95M Buy
120,716
+44,378
+58% +$2.51M ﹤0.01% 2092
2025
Q1 		$4.45M Sell
76,338
-8,219
-10% -$561K ﹤0.01% 2398
2024
Q4 		$6.81M Sell
84,557
-8,532
-9% -$729K ﹤0.01% 2119
2024
Q3 		$7.46M Buy
93,089
+7,762
+9% +$551K ﹤0.01% 2064
2024
Q2 		$5.21M Buy
85,327
+26,479
+45% +$1.57M ﹤0.01% 2271
2024
Q1 		$2.91M Buy
58,848
+10,927
+23% +$520K ﹤0.01% 2678
2023
Q4 		$2.01M Buy
47,921
+4,590
+11% +$156K ﹤0.01% 2869
2023
Q3 		$1.42M Buy
43,331
+7,662
+21% +$261K ﹤0.01% 2985
2023
Q2 		$1.26M Buy
35,669
+8,434
+31% +$279K ﹤0.01% 3077
2023
Q1 		$773K Buy
+27,235
New +$961K ﹤0.01% 3263

Other funds holding PRCT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $86.1B AUM 29.11% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Ameriprise's PRCT Position: Q1 2026 in Review

Ameriprise reduced its Procept Biorobotics (PRCT) stake by 8.8% in Q1 2026, selling an estimated $96.2K and leaving 35,599 shares worth $890K. The position accounts for ﹤0.01% of the portfolio, ranked #3351.

Ameriprise first reported a position in PRCT in Q1 2023 and has held it in 13 quarters since. The position peaked at $7.46M in Q3 2024. 256 funds tracked by Wall St. Rank hold PRCT as of Q1 2026.

  • Ameriprise held 35,599 shares of Procept Biorobotics worth $890K as of Q1 2026.
  • Ameriprise sold 3,414 Procept Biorobotics shares in Q1 2026, an estimated $96.2K.
  • Procept Biorobotics made up ﹤0.01% of Ameriprise's portfolio in Q1 2026, its #3351 holding.
  • Ameriprise first reported a position in Procept Biorobotics in Q1 2023 and has held it in 13 quarters since.
  • Ameriprise's Procept Biorobotics position peaked at $7.46M in Q3 2024.
  • 256 funds tracked by Wall St. Rank held Procept Biorobotics as of Q1 2026.

Based on Ameriprise's 13F filing for Q1 2026, filed 15 May 2026.